SVRA vs ZYME

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 22, 2026

SVRA

68.1
AI Score
VS
SVRA Wins

ZYME

35.2
AI Score

Investment Advisor Scores

SVRA

68score
Recommendation
HOLD

ZYME

35score
Recommendation
AVOID NEW MONEY

AI Analyst Insights

Detailed Metrics Comparison

Metric SVRA ZYME Winner
Forward P/E 0.4076 20.8333 SVRA
PEG Ratio 0 0 Tie
Revenue Growth 0.0% -90.6% SVRA
Earnings Growth 0.0% 0.0% Tie
Tradestie Score 68.1/100 35.2/100 SVRA
Profit Margin 0.0% 0.0% Tie
Beta 1.00 1.00 Tie
AI Recommendation HOLD AVOID NEW MONEY SVRA

Relative Price Performance (Last 90 Days)

SVRA 1M: -9.2% · 3M: -17.6% ZYME 1M: +3.4% · 3M: +24.4%

Current Technical Phase

SVRA

Markdown
Sell / avoid

Price below a falling SMA50 (slope -5.4%), weak momentum, RSI 38

RSI (14): 37.9 · Price: $4.54

ZYME

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (4.4% over 20 days), RSI 61

RSI (14): 61.0 · Price: $28.44

Fundamentals Snapshot

Metric SVRA ZYME
Market Cap — —
Forward P/E -12.4 31.5
Trailing P/E — —
Revenue (TTM) — —
Revenue Growth 0.0% -0.9%
Gross Margin -86843.0% -2.5%
Operating Margin 0.0% -9.2%
EPS -0.58 -2.02
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, SVRA is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.